Sanro Health announced an investment from Topcon Healthcare that aims to accelerate the transformation of ophthalmic data into actionable insights that drive better patient outcomes and more efficient clinical research.

Specific terms of the investment were not disclosed. 

Sanro Health said it is addressing fragmented ophthalmic clinical data, which it calls one of healthcare’s biggest challenges. By uniting medical images and health records within a single, interoperable framework, the company enables clinicians and researchers to leverage connected data while preserving patient context and ensuring data integrity. This unified approach supports trustworthy, standards-based biomarker discovery and real-world AI applications.

Sanro Health’s flagship product, the Sanro Optimizer, integrates electronic health record (EHR) and imaging data to create intelligent patient profiles and ranked cohorts. This platform is designed to allow eyecare providers to identify eligible participants for clinical trials in real time, seamlessly within the flow of patient care. The Optimizer serves as a foundation for real-world AI, harnessing Sanro’s proprietary interoperability and AI framework to enable more personalized research and patient care.

“Sanro Health’s deep understanding of ophthalmic data, and proven ability to deliver real-world clinical data and medical image interoperability make them an ideal partner,” said Ali Tafreshi, CEO & President of Topcon Healthcare, Inc. “By linking these data sets using agreed data standards, we can transform how patient care and research interconnect.”

According to Topcon, the collaboration strengthens its 'Healthcare from the Eye' strategy, an initiative to leverage ophthalmic data as a window into overall health, while fueling Sanro Health’s US expansion and accelerating its product development roadmap. Together, the companies aim to make connected, standards-based data the foundation for enhanced patient care and cutting-edge clinical research.